

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1.-58. (Canceled)

59. (Previously Presented) A composition comprising:

(a) genistein;

(b) one or more of:

(i) a compound that increases expression of a CFTR in an epithelial cell; and

(ii) a chemical chaperone that increases trafficking of a CFTR to a plasma membrane in an epithelial cell; and

(c) a physiologically acceptable carrier.

60. (Previously Presented) A composition comprising:

(a) quercetin;

(b) one or more of:

(i) a compound that increases expression of a CFTR in an epithelial cell; and

(ii) a chemical chaperone that increases trafficking of a CFTR to a plasma membrane in an epithelial cell; and

(c) a physiologically acceptable carrier.

61. (Previously Presented) A composition comprising:

(a) apigenin;

(b) one or more of:

(i) a compound that increases expression of a CFTR in an epithelial cell; and

(ii) a chemical chaperone that increases trafficking of a CFTR to a plasma membrane in an epithelial cell; and

(c) a physiologically acceptable carrier.

62. (Previously Presented) A composition comprising:

(a) kaempferol;

(b) one or more of:

(i) a compound that increases expression of a CFTR in an epithelial cell; and

(ii) a chemical chaperone that increases trafficking of a CFTR to a plasma membrane in an epithelial cell; and

(c) a physiologically acceptable carrier.

63. (Previously Presented) A composition comprising:

(a) biochanin A;

(b) one or more of:


(i) a compound that increases expression of a CFTR in an epithelial cell; and


(ii) a chemical chaperone that increases trafficking of a CFTR to a plasma membrane in an epithelial cell; and

(c) a physiologically acceptable carrier.

64. (Currently Amended) A composition comprising:

(a) a polyphenolic compound having the formula:





wherein carbon atoms at positions 2, 3, 5, 6, 7, 8, 2', 3', 4', 5' and 6' are bonded to a moiety independently selected from the group consisting of hydrogen atoms, hydroxyl groups and methoxyl groups, and wherein X is a single bond or a double bond, or a stereoisomer of any of the foregoing polyphenolic compounds;

(b) a compound selected from the group consisting of resveratrol, ascorbic acid, ascorbate salts and dehydroascorbic acid; and

(c) a physiologically acceptable carrier;

wherein said composition does not consist essentially of quercetin in combination with ascorbic acid.

65. (Currently Amended) A method for treating cystic fibrosis in a mammal, comprising administering to a mammal a composition comprising a physiologically acceptable carrier or excipient in combination with:

a. one or more compounds selected from the group consisting of flavones and isoflavones, wherein the compound is capable of stimulating chloride secretion; and

b. one or more of

(i) a substance that increases trafficking of a CFTR to the plasma membrane of epithelial cells; and

(ii) a substance that increases expression of a CFTR in epithelial cells;

thereby treating cystic fibrosis in a mammal.

66. (Previously Presented) The method according to claim 65, wherein the substance increases expression of a CFTR in the cells and is selected from the group consisting of 4-phenylbutyrate and sodium butyrate.

67. (Previously Presented) The method according to claim 65, wherein the substance is a chemical chaperone that increases trafficking of a CFTR to the plasma membrane of the cells, and wherein the compound is selected from the group consisting of glycerol, dimethylsulfoxide, trimethylamine N-oxide, taurin, methylamine and deoxyspergualin.